期刊
CANCERS
卷 11, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cancers11121934
关键词
JAK2; STAT3; STAT5B; HPV; cervical cancer
类别
资金
- Medical Research Council (MRC) [MR/K012665, MR/S001697/1]
- Wellcome Trust studentship [1052221/Z/14/Z]
- Wellcome Institutional Strategic Support Fund (ISSF) [204825/Z/16/Z]
- Wellcome Trust [204825/Z/16/Z] Funding Source: Wellcome Trust
- MRC [MR/S001697/1, MR/K012665/1] Funding Source: UKRI
Persistent infection with high-risk human papillomavirus (HPV) is the underlying cause of similar to 5% of all human cancers, including the majority of cervical carcinomas and many other ano-genital and oral cancers. A major challenge remains to identify key host targets of HPV and to reveal how they contribute to virus-mediated malignancy. The HPV E6 oncoprotein aberrantly activates the signal transducer and activator of transcription 3 (STAT3) transcription factor and this is achieved by a virus-driven increase in the levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in HPV positive cervical cancers cells. Crucially, STAT3 activity is essential for the proliferation and survival of cervical cancer cells, suggesting that targeting STAT3 may have therapeutic potential. Unfortunately, the development of direct STAT3 inhibitors has been problematic in the clinic due to toxicity issues identified in early stage trials. To overcome this issue, we focused on the protein Janus kinase 2 (JAK2), which phosphorylates STAT3 and is essential for STAT3 activation. Here, we demonstrate that inhibiting JAK2 reduces cell proliferation and induces apoptosis in HPV transformed cervical cancer cells. We further establish that this is due to inhibition of phosphorylation of the JAK2 substrates STAT3 and STAT5. Finally, we demonstrate that the clinically available JAK2 inhibitor Ruxolitinib synergises with cisplatin in inducing apoptosis, highlighting JAK2 as a promising therapeutic target in HPV-driven cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据